136 related articles for article (PubMed ID: 23797529)
1. The role of CYP2C8 genotypes in dose requirement and levels of everolimus after heart transplantation.
Kniepeiss D; Wagner D; Wasler A; Tscheliessnigg KH; Renner W
Wien Klin Wochenschr; 2013 Jul; 125(13-14):393-5. PubMed ID: 23797529
[TBL] [Abstract][Full Text] [Related]
2. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation.
Kniepeiss D; Renner W; Trummer O; Wagner D; Wasler A; Khoschsorur GA; Truschnig-Wilders M; Tscheliessnigg KH
Clin Transplant; 2011; 25(1):146-50. PubMed ID: 20041908
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients.
Moes DJ; Press RR; den Hartigh J; van der Straaten T; de Fijter JW; Guchelaar HJ
Clin Pharmacokinet; 2012 Jul; 51(7):467-80. PubMed ID: 22624503
[TBL] [Abstract][Full Text] [Related]
4. The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients.
Schoeppler KE; Aquilante CL; Kiser TH; Fish DN; Zamora MR
Clin Transplant; 2014 May; 28(5):590-7. PubMed ID: 24628014
[TBL] [Abstract][Full Text] [Related]
5. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
Schweiger M; Wasler A; Prenner G; Stiegler P; Stadlbauer V; Schwarz M; Tscheliessnigg K
Transpl Immunol; 2006 Jun; 16(1):46-51. PubMed ID: 16701176
[TBL] [Abstract][Full Text] [Related]
6. Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation.
Eisen H
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii9-13. PubMed ID: 16815858
[TBL] [Abstract][Full Text] [Related]
7. Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction.
Kovarik JM
Drugs Today (Barc); 2004 Feb; 40(2):101-9. PubMed ID: 15045032
[TBL] [Abstract][Full Text] [Related]
8. Everolimus: an immunosuppressive agent in transplantation.
Patel JK; Kobashigawa JA
Expert Opin Pharmacother; 2006 Jul; 7(10):1347-55. PubMed ID: 16805720
[TBL] [Abstract][Full Text] [Related]
9. Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers.
Dorado P; Cavaco I; Cáceres MC; Piedade R; Ribeiro V; Llerena A
Eur J Clin Pharmacol; 2008 Oct; 64(10):967-70. PubMed ID: 18548238
[TBL] [Abstract][Full Text] [Related]
10. Influence of CYP3A5 genetic variation on everolimus maintenance dosing after cardiac transplantation.
Lesche D; Sigurdardottir V; Setoud R; Englberger L; Fiedler GM; Largiadèr CR; Mohacsi P; Sistonen J
Clin Transplant; 2015 Dec; 29(12):1213-20. PubMed ID: 26458301
[TBL] [Abstract][Full Text] [Related]
11. Late acute cardiac allograft rejection: new therapeutic options?
Schweiger M; Wasler A; Prenner G; Tripolt M; Schwarz M; Tscheliessnigg KH
Transplant Proc; 2005 Dec; 37(10):4528-31. PubMed ID: 16387161
[TBL] [Abstract][Full Text] [Related]
12. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study.
Potena L; Prestinenzi P; Bianchi IG; Masetti M; Romani P; Magnani G; Fallani F; Coccolo F; Russo A; Ponticelli C; Rapezzi C; Grigioni F; Branzi A
J Heart Lung Transplant; 2012 Jun; 31(6):565-70. PubMed ID: 22341702
[TBL] [Abstract][Full Text] [Related]
14. Everolimus in clinical practice in long-term liver transplantation: an observational study.
Casanovas T; Argudo A; Peña-Cala MC
Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
[TBL] [Abstract][Full Text] [Related]
15. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.
Eisen HJ; Tuzcu EM; Dorent R; Kobashigawa J; Mancini D; Valantine-von Kaeppler HA; Starling RC; Sørensen K; Hummel M; Lind JM; Abeywickrama KH; Bernhardt P;
N Engl J Med; 2003 Aug; 349(9):847-58. PubMed ID: 12944570
[TBL] [Abstract][Full Text] [Related]
16. Everolimus in cardiac-transplant recipients.
Banas B; Böger C; Krämer B
N Engl J Med; 2003 Dec; 349(23):2271-2; author reply 2271-2. PubMed ID: 14657441
[No Abstract] [Full Text] [Related]
17. [Level of evidence for therapeutic drug monitoring of everolimus].
Goirand F; Royer B; Hulin A; Saint-Marcoux F;
Therapie; 2011; 66(1):57-61. PubMed ID: 21466779
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses.
Majewski M; Korecka M; Joergensen J; Fields L; Kossev P; Schuler W; Shaw L; Wasik MA
Transplantation; 2003 May; 75(10):1710-7. PubMed ID: 12777861
[TBL] [Abstract][Full Text] [Related]
19. Renal recovery after conversion to an everolimus-based immunosuppression in early and late heart transplant recipients: a 12-month analysis.
Michel S; Bigdeli AK; Hagl C; Meiser B; Kaczmarek I
Exp Clin Transplant; 2013 Oct; 11(5):429-34. PubMed ID: 24128136
[TBL] [Abstract][Full Text] [Related]
20. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range.
Kovarik JM; Kaplan B; Tedesco Silva H; Kahan BD; Dantal J; Vitko S; Boger R; Rordorf C
Transplantation; 2002 Mar; 73(6):920-5. PubMed ID: 11923693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]